Bastiaan Jeroen van der Baan - 30 Jun 2023 Form 4 Insider Report for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Role: Director
Signature: /s/ Bastiaan van der Baan
Issuer symbol: LIXT
Transactions as of: 30 Jun 2023
Net transactions value: $0
Form type: 4
Filing time: 07 Jul 2023, 14:52:14 UTC
Previous filing: 05 Jan 2023
Next filing: 27 Sep 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LIXT	Options to Purchase Common Stock	Award	$0	+10,000		$0.000000	10,000	30 Jun 2023	Common	10,000	$5.88	Direct	F1
transaction	LIXT	Options to Purchase Common Stock	Award	$0	+25,000		$0.000000	25,000	17 Jun 2022	Common	25,000	$7.40	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Explanation of Responses: Effective June 30, 2023, the reporting person was granted stock options to purchase an aggregate of 10,000 shares, vesting on the last day of each subsequent quarter until fully vested (e.g. vesting to start on September 30, 2023). Effective June 2, 2023, the Issuer effected a 1-for-10 reverse split of its outstanding shares of common stock. Accordingly, the exercise price and the amount of underlying shares of Common Stock set forth above have been adjusted to reflect the reverse split.

Content

Explanation of Responses: Effective June 30, 2023, the reporting person was granted stock options to purchase an aggregate of 10,000 shares, vesting on the last day of each subsequent quarter until fully vested (e.g. vesting to start on September 30, 2023). Effective June 2, 2023, the Issuer effected a 1-for-10 reverse split of its outstanding shares of common stock. Accordingly, the exercise price and the amount of underlying shares of Common Stock set forth above have been adjusted to reflect the reverse split.